Effect of Bendopnea on Achievement Medical Treatment Target Doses in Heart Failure

Background: The newly described bendopnea in heart failure (HF) is associated with increased cardiac filling pressures. The aim of the study was to show the effect of bendopnea follow-up on reaching optimal medical treatment doses in HF. Methods: A total of 413 patients were screened, and we included 203 patients with HF who were previously evaluated for bendopnea. Demographic data, presence or absence of bendopnea, medical history, laboratory findings, and medical treatments were evaluated. Optimal medical therapy target doses at baseline and 3rd month were compared in groups with and without bendopnea. Results: On admission, 64 patients (31.5%) had bendopnea. The rate of patients with bendopnea decreased in the 3rd month (n = 42, 20.7%). The proportion of patients who used at least 50% of the recommended medical treatment dose on admission and in the 3rd month was compared; angiotensin-converting enzyme inhibitor /angiotensin receptor blockers use increased from 40.6% to 71.9% in those with bendopnea (P = 0.013), from 56.1% to 81.3% in those without bendopnea (P < 0.001) and beta-blockers use increased from 28.2% to 60.9% in those with bendopnea (P = 0.042), from 31.6% to 69.8% in those without bendopnea (P < 0.001). However, aldosterone antagonists use decreased from 70.3% to 67.2% in those with bendopnea (P = 0.961), from 68.4 % to 64.1% in those without bendopnea (P = 0.334). Bendopnea was independently effective in achieving ACE-I/ARB target doses (OR: 0.359, CI 95%: 0.151-0.854, P = 0.020). Conclusion: Bendopnea follow-up in HF patients can provide a significant improvement in reaching the recommended treatment target doses.